Clinical Trials
3 trialsNCT04135092 2020-09-04
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
No longer available
NCT02083484 2018-01-26
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Merck Sharp & Dohme LLC
No longer available
NCT03311542 2018-01-10
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
No longer available